2026-05-12T01:33:31Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/192422025-04-04T17:56:44Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Barreiro-Pérez, Manuel author Pastor Pueyo, Pablo author Raposeiras-Roubín, Sergio author Montero Corominas, Dolores author Uribarri, Aitor author Eiros-Bachiller, Rocio author Rozado Castaño, José author García-Cuenllas Álvarez, Luisa author Serratosa Fernández, Luis author Domínguez, Fernando author Pascual-Figal, Domingo A author 2023-07 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccine administration. Because of the high prevalence of COVID-19, the expansion of vaccination programs, and the appearance of new information on myocarditis in these contexts, there is a need to condense the knowledge acquired since the start of the pandemic. To meet this need, this document was drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology, with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS). The document aims to address the diagnosis and treatment of cases of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration. Rev Esp Cardiol. 2023 Jul;76(7):555-563. 10.1016/j.recesp.2023.01.010 1579-2242 Revista espanola de cardiologia 36743295 http://hdl.handle.net/20.500.12105/19242 Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management